A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the best dose of Vitamin D to give to hip fracture patients to achieve the optimal therapeutic level.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamilton Health Sciences Corporation
• Collaborator: Merck Frosst Canada Ltd.
• Treatments: Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Fragility hip fracture patient

• Previous Vitamin D supplementation is okay.

Exclusion Criteria:

• Patients with pathological fracture secondary to malignancy or intrinsic bone disease (eg. Paget's disease)

• Cancer in the past 10 years likely to metastasize to bone

• Renal insufficiency (creatinine <30 mls/min)

• Hypercalcemia (primary hyperparathyroidism; granulomatous diseases; drug-induced such as lithium, thiazides), hypocalcemia, hypercalciuria, fracture or stroke within the last 3 months

• Hormone replacement therapy, calcitonin, fluoride, or bisphosphonates during the previous 24 months

• Pre-existing bone abnormality

• Renal stones in past 10 years